Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 18/20 | 0.64 |
| ▸ | TDO2 | P48775 | 18/20 | 0.64 |
| ▸ | IDO2 | Q6ZQW0 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13839583 | 0.91 | IDO1 (0.58) | IDO1TDO2IDO2 | |
| SCHEMBL98309 | 0.86 | IDO1 (0.74) | IDO1TDO2IDO2 | |
| Hydrochloric Acid SCHEMBL7227619 | 0.84 | IDO1 (0.75) | IDO1TDO2IDO2 | |
| SCHEMBL11500414 | 0.82 | LMNA (0.46) | IDO1TDO2 | |
| SCHEMBL20118854 | 0.81 | IDO1 (0.48) | IDO1TDO2IDO2 | |
| SCHEMBL13697238 | 0.80 | MLKL (0.51) | IDO1TDO2 | |
| SCHEMBL14041261 | 0.78 | IDO1 (0.83) | IDO1TDO2IDO2 | |
| SCHEMBL14380217 | 0.78 | MEN1 (0.43) | IDO1TDO2 | |
| SCHEMBL11781680 | 0.78 | KDM4E (0.46) | IDO1TDO2 | |
| SCHEMBL3482548 | 0.78 | MEN1 (0.43) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3011961-B1 | 4F-BENZOYL-TN14003 FOR THE MOBILISATION OF HEMATOPOIETIC PROGENITOR CELLS IN VIEW OF TRANSPLANTATION | BIOKINE THERAPEUTICS LTD (IL) | 2020-11-11 | — | — | EP | disclosed |
| EP-2841084-B1 | CXCR4 ANTAGONIST PEPTIDE FOR USE IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD (IL) | 2018-05-30 | — | — | EP | disclosed |
| US-9439942-B2 | Peptides and use thereof in the treatment of large cell lung cancer | BIOKINE THERAPEUTICS LTD. (IL) | 2016-09-13 | — | — | US | disclosed |
| US-9427456-B2 | Peptide therapy for increasing platelet levels | BIOKINE THERAPEUTICS LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| EP-3011961-A1 | 4F-benzoyl-TN14003 for the mobilisation of hematopoietic progenitor cells in view of transplantation | Biokine Therapeutics LTD. (IL) | 2016-04-27 | — | — | EP | disclosed |
| EP-2942059-A1 | 4F-BENZOYL-TN14003 FOR USE IN THE TREATMENT OF MULTIPLE MYELOMA | Biokine Therapeutics LTD. (IL) | 2015-11-11 | — | — | EP | disclosed |
| US-9034814-B2 | CXCR4 antagonists for wound healing and re-epithelialization | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2015-05-19 | — | — | US | disclosed |
| US-20150125549-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | BIOKINE THERAPEUTICS LTD. (IL) | 2015-05-07 | — | — | US | disclosed |
| EP-2841084-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | Biokine Therapeutics Ltd. (IL) | 2015-03-04 | — | — | EP | disclosed |
| EP-2426139-B1 | CXCR4 antagonist and use thereof | BIOKINE THERAPEUTICS LTD (IL) | 2014-10-01 | — | — | EP | disclosed |
| WO-2008075369-A2 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR BONE MARROW RECOVERY | BIOKINE THERAPEUTICS LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008075371-A2 | T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR IMMUNOMODULATION | BIOKINE THERAPEUTICS LTD. (IL) | 2008-06-26 | — | — | WO | disclosed |
| EP-1898943-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | Hadasit Medical Research Services & Development Ltd. (IL) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006126188-A2 | CXCR4 ANTAGONISTS FOR WOUND HEALING AND RE-EPITHELIALIZATION | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2006-11-30 | — | — | WO | disclosed |
| US-20060264378-A1 | Cxcr4 antagonist and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-23 | — | — | US | disclosed |
| EP-1541585-A1 | CXCR4 ANTAGONIST AND USE THEREOF | Fujii, Nobutaka (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6582700-B1 | A linear core chain having two or more side chains pending directly from different points on the linear core chain. Each of the side chains comprises an epitopic site of an antigen or a peptide. The synthetic constructs are monomeric units that | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2003-06-24 | — | — | US | disclosed |
| EP-1032422-A4 | LINEAR ANTIGEN SUPPORTING UNITS | UNIV SOUTH CAROLINA (US) | 2003-02-05 | — | — | EP | disclosed |
| EP-1032422-A1 | LINEAR ANTIGEN SUPPORTING UNITS | MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) | 2000-09-06 | — | — | EP | disclosed |
| WO-1999025381-A1 | LINEAR ANTIGEN SUPPORTING UNITS | MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) | 1999-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264378-A1 | Cxcr4 antagonist and use thereof | CXCR4, ACKR3, CXCR1 | IDO1 3114/4885TDO2 4879/4885IDO2 3132/4885 |
| US-20150125549-A1 | PEPTIDES AND USE THEREOF IN THE TREATMENT OF LARGE CELL LUNG CANCER | NGLY1, VIP, TAP1 | IDO1 3364/4885TDO2 4847/4885IDO2 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.